

## PRESS RELEASE

### 2009 third-quarter sales

Villepinte, 13 November 2009

#### Consolidated Group sales (IFRS):

In thousands of euros	2009	2008	Change
First quarter .....	79,031	75,573	+4.6%
Second quarter .....	83,485	81,376	+2.6%
Third quarter .....	81,997	79,160	+3.6%
<b>First nine months.....</b>	<b>244,513</b>	<b>236,109</b>	<b>+3.6%</b>

#### Consolidated sales by region

In thousands of euros	2009	2008	Change
European subsidiaries.....	191,120	186,969	+2.2%
Other markets .....	53,393	49,140	+8.7%
<b>First nine months.....</b>	<b>244,513</b>	<b>236,109</b>	<b>+3.6%</b>

#### 2009 third-quarter sales highlights and outlook

Dotarem has maintained sustained growth in volume (+17.7%) and in value (+10.1%) compared to the same period last year. This trend confirms Dotarem position as the European leader in the MRI segment with a 38% market share in Europe in the 2009 first half, gaining a further 5 points over the first half of 2008.

Xenetix sales accelerated, increasing 17.3% in volume in the quarter (+4.4% in value) to achieve year-to-date nine-month growth of 15.6% (+2.6% in value). Reflecting this momentum, Xenetix also added market share, particularly in Europe.

Group revenue overall in the 2009 third quarter grew 3.6%. Excluding currency effects, revenue grew 4.1%.

Europe, the Group's primary market, experienced a period of consolidation in the third quarter, particularly for sales to agents. The German subsidiary has continued to deliver rapid growth in sales (+9.4%).

The Group's strongest growth has been achieved in Asia (+20.57% year-to-date), driven notably by the expansion of sales in China.

On this basis, the Group confirms its guidance for annual sales in line with the prior year.

**Contact:** Finance Department. Tel: +33 (0) 1 45 91 50 11